| Original language | English (US) |
|---|---|
| Article number | e3 |
| Pages (from-to) | e3 |
| Journal | Molecular Therapy Nucleic Acids |
| Volume | 1 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2012 |
Bibliographical note
Funding Information:We thank Drs Voytas, Aronovich, Carroll, and Kim, as well as the journal reviewers and several other colleagues who attended the recent Singapore Conference on Genome Engineering for critical reading of the manuscript and making significant suggestions. We especially thank Drs Voytas and Carroll for clarification of some aspects of the molecular biology of targeted nucleases and historical and balanced perspectives on their development. The work in the authors’ labs is funded by NIH grants 1R41DK081249 (P.B.H.) and 1R41HL108440 (S.C.F.). All three authors hold stock in Recombinetics Inc., whose unfunded business plan includes genetic modification of animal genomes using site-directed nucleases such as ZFNs and TALENs. Scott Fahrenkrug and Perry Hackett are cofounders of Recombinetics and are officers of the company, CEO and CSO, respectively. Please note that in the time since the last revision, Recombinetics has signed a licensing deal with Cellectis Bioresearch, a commercial provider of engineered meganucleases and TALENs. According to the press release describing this agreement, “Recombinetics will use Cellectis Bioresearch's engineered nucleases to conceive animals with improved genetic features.”